Contemporary use of guideline‐based higher potency P2Y12 receptor inhibitor therapy in patients with moderate‐to‐high risk non‐ST‐segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross‐sectional study

Background After myocardial infarction, guidelines recommend higher‐potency P2Y12 receptor inhibitors, namely ticagrelor and prasugrel, over clopidogrel. Hypothesis We aimed to determine the contemporary use of higher‐potency antiplatelet therapy in Canadian patients with non‐ST‐elevation myocardial...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cardiology (Mahwah, N.J.) N.J.), 2021-06, Vol.44 (6), p.839-847
Hauptverfasser: Patel, Ashish, Goodman, Shaun G., Tan, Mary, Suskin, Neville, McKelvie, Robert, Mathew, Andrew L., Lutchmedial, Sohrab, Dehghani, Payam, Lavoie, Andrea J., Huynh, Thao, Lavi, Shahar, Philipp, Roger, Khan, Razi, Yan, Andrew T., Radhakrishnan, Sam, Sedlak, Tara, Brunner, Nathan, Kim, Hahn Hoe, Cieza, Tomas, Kassam, Saleem, Fordyce, Christopher B., Heffernan, Michael, Jedrzkiewicz, Sean, Madan, Mina, Ahmed, Shaheeda, Barry, Colin, Dery, Jean‐Pierre, Bagai, Akshay
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background After myocardial infarction, guidelines recommend higher‐potency P2Y12 receptor inhibitors, namely ticagrelor and prasugrel, over clopidogrel. Hypothesis We aimed to determine the contemporary use of higher‐potency antiplatelet therapy in Canadian patients with non‐ST‐elevation myocardial infarction (NSTEMI). Methods A total of 684 moderate‐to‐high risk NSTEMI patients were enrolled in the prospective Canadian ACS Reflective II registry at 12 Canadian hospitals and three clinics in five provinces between July 2016 and May 2018. Multivariable logistic regression modeling was performed to assess factors independently associated with higher‐potency P2Y12 receptor inhibitor use at discharge. Results At hospital discharge, 78.3% of patients were treated with a P2Y12 receptor inhibitor. Among patients discharged on a P2Y12 receptor inhibitor, use of higher‐potency P2Y12 receptor inhibitor was 61.4%. After adjustment, treatment in‐hospital with PCI (OR 4.48, 95%CI 3.34–6.03, p 
ISSN:0160-9289
1932-8737
DOI:10.1002/clc.23618